GeneDx (WGS) to Release Quarterly Earnings on Tuesday

GeneDx (NASDAQ:WGS) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $82.24 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

GeneDx Stock Up 14.5 %

NASDAQ:WGS opened at $68.15 on Tuesday. GeneDx has a 1 year low of $3.86 and a 1 year high of $98.87. The stock has a 50-day moving average price of $76.76 and a two-hundred day moving average price of $59.75. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -21.91 and a beta of 2.01. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on WGS shares. Wells Fargo & Company boosted their price objective on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Craig Hallum upped their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. The Goldman Sachs Group raised their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, TD Cowen upped their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $70.67.

Insider Transactions at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 1,657 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the transaction, the chief executive officer now owns 3,937 shares of the company’s stock, valued at $308,975.76. The trade was a 29.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin Feeley sold 1,137 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total value of $86,832.69. Following the completion of the sale, the chief financial officer now directly owns 24,731 shares of the company’s stock, valued at approximately $1,888,706.47. The trade was a 4.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 363,669 shares of company stock valued at $28,061,081 over the last 90 days. 27.30% of the stock is owned by corporate insiders.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.